In early June there were a number of Jakafi posters presented as ASCO, all of which are available from our website. One I want to highlight which is also the subject of an oral presentation at EHA is for the ongoing Phase II study in patients with baseline platelet counts between 50,000 and 100,000 who as you may recall were excluded from the Phase III trials but are part of the indication in the label. In this study we start patients with a dose of 5 mg twice daily and allow for dose modifications based on adequate platelet counts.
At the time of this interim analysis the majority of patients had optimized their dose to 10 mg twice daily or higher, and for patients completing the week 24 visit most experienced reductions in spleen size and improvements in symptoms to a degree that is comparable to what we saw at 15 mg and 20 mg twice a day in the Phase III trials. I’ll now turn the call over to Pat who will provide you with more details on the launch; Dave will follow with an update about our financial performance for Q2, and I’ll conclude by providing an update on our other ongoing programs. Pat?
Thanks, Paul. Good morning. We’re going to start with a few metrics that may help you appreciate the basis for the guidance we’re now providing. I’m pleased to say that we were able to increase the number of physicians who have used Jakafi from over 1000 reported in Q1 to over 1600 in Q2. We’re building a broad base of subscribers, of which about 80% are from the community; and since launch, these community hematologists/oncologists have generated about 75% of the prescription volumes.Read the rest of this transcript for free on seekingalpha.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV